Selexipag denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for selexipag are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Issue a "Not FDA-Approved" Denial for Selexipag

Selexipag holds FDA approval for pulmonary arterial hypertension (PAH). A "not FDA-approved" denial in this context almost always reflects one of three administrative errors: (1) the claim was coded in a way that suggests an off-label use, (2) the diagnosis codes on the prior authorization did not align with the approved indication, or (3) the plan's system failed to recognize the approved indication. This type of denial is often correctable without a full formal appeal.

## Why This Denial Is Appealable — and Likely Reversible

Because selexipag does carry FDA approval for PAH, a denial asserting it is "not FDA-approved" for that indication is factually incorrect when the diagnosis is properly documented. This makes the denial particularly strong to challenge on internal appeal, and if escalated, on external review, where an independent reviewer will look at the FDA label directly.

## Your Federal Appeal Rights

• Internal appeal (first step): Submit a copy of the FDA-approved prescribing information and the applicable ICD-10 diagnosis code confirming PAH. Request that Humana reverse the denial as an administrative error.
• ACA §2719 / External Review: If the internal appeal fails, you have approximately four months from the denial to request independent external review. An external reviewer will apply the FDA label and is not bound by Humana's internal coverage policies.
• ERISA §503 (employer plans): You are entitled to the full claim file and written reasoning. Request the specific clinical evidence Humana relied upon to conclude the use was not FDA-approved.
• Expedited review: Available for urgent clinical situations.

## Appeal Timeline

1. Immediately contact Humana to confirm the specific basis for the denial — obtain this in writing. 2. File the internal appeal with the FDA labeling and correct diagnosis documentation attached. 3. If unresolved within the plan's stated internal review window, escalate to external review without delay.

## Documentation to Gather

• FDA prescribing information: Print the current FDA-approved label for selexipag confirming the PAH indication.
• Diagnosis documentation: Physician records and coding confirming the PAH diagnosis that triggers the approved indication.
• Prior authorization submission records: Confirm that the correct indication and diagnosis codes were submitted.
• Prescriber clarification letter: A short letter from the prescriber affirming that selexipag is being used for its FDA-approved indication in this patient.

## Criteria-Mapping Structure

In your appeal letter, present a two-column table: in the first column, quote the relevant portion of the FDA label describing the approved indication; in the second column, document the specific chart evidence confirming the patient's diagnosis falls within that indication. This makes the mismatch between Humana's denial rationale and the actual FDA approval status immediately apparent to any reviewer.